Rong Liu
About Rong Liu
Rong Liu is the Senior Director of Biostatistics at Bristol Myers Squibb, with a strong background in quantitative sciences and medical practice.
Title at Bristol Myers Squibb
Rong Liu serves as the Senior Director of Biostatistics at Bristol Myers Squibb. She has held this position since November 2019 and is based in the Whippany, NJ office. In her role, she leads biostatistics efforts focused on the full development of key treatments such as Opdivo-Yervoy for melanoma and GU-bladder cancer.
Previous Roles in Biostatistics
Before joining Bristol Myers Squibb, Rong Liu was the Director of Biostatistics at Celgene from 2018 to 2019 in New Jersey. Prior to that, she worked at Bayer Pharmaceuticals in Whippany, NJ, where she held positions including Associate Director and Deputy Director of Biostatistics from 2014 to 2018. Liu also has a significant tenure at Merck, serving in various roles such as Biometrician, Sr Biometrician, and Principal Statistician between 2006 and 2013.
Educational Background in Biostatistics and Medicine
Rong Liu has a robust educational background in the fields of biostatistics and medicine. She earned her PhD and MS in Biostatistics and Statistics from the University of Virginia between 1996 and 1999. Earlier, she completed her M.D. in Medicine at Shandong University, where she studied from 1991 to 1996.
Experience in Oncology and Hematology
With extensive experience in biostatistics, Rong Liu has worked across multiple therapeutic areas, including oncology and hematology. At Bristol Myers Squibb, she also heads the biostatistics team focused on early development in hematology and cell therapy, contributing to significant advancements in these critical fields.
Professional Journey in Biostatistics
Rong Liu has built a distinguished career in biostatistics over more than a decade. Her professional journey includes leadership roles at major pharmaceutical companies, where she has developed her expertise in quantitative sciences and medical practice. Her contributions to the development of treatments in oncology and hematology highlight her role as a key figure in biostatistics.